Beyond Disease Control in Chronic Myeloid Leukemia: Real-World Quality of Life Across TKIs and Treatment-Free Remission

Abstract excerpt

<title>Abstract</title> <p>Background Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) into a chronic condition with near-normal life expectancy. As patients remain on therapy for years, health-related quality of life (HRQoL) and patient-reported outcomes (PROs) are increasingly important in therapeutic decision-making. However, real-world data comparing HRQoL across different TK...

Topics

Open a Topic to create a Post that cites this publication.

• Antineoplastic Combined Chemotherapy Protocols
• Clinical Trials as Topic
• Early Detection of Cancer
• Fusion Proteins, bcr-abl
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Protein Kinase Inhibitors
• Recurrence
• Remission Induction

Identifiers and source

Literature Corpus work

7a7a1789-2a66-5753-b09c-2d4ee4cc4dc1

DOI

10.21203/rs.3.rs-9730879/v1